Brief: Fulcrum Therapeutics Signs Exclusive Global License Agreement In Rare Hematology

Fulcrum Therapeutics

10/07/2023 12:32

July 10 (Reuters) - Fulcrum Therapeutics Inc  FULC.O :
    * FULCRUM THERAPEUTICS SIGNS EXCLUSIVE GLOBAL LICENSE
AGREEMENT IN
RARE HEMATOLOGY
    * FULCRUM THERAPEUTICS INC - ENTERED INTO A WORLDWIDE,
EXCLUSIVE
LICENSE AGREEMENT WITH CAMP4 THERAPEUTICS CORP.
    * FULCRUM THERAPEUTICS INC - HAS BEEN GRANTED AN EXCLUSIVE,
WORLDWIDE LICENSE TO INTELLECTUAL PROPERTY ARISING FROM CAMP4'S
DBA PROGRAM
    * FULCRUM THERAPEUTICS INC - CAMP4 THERAPEUTICS WILL RECEIVE
AN
UNDISCLOSED UPFRONT PAYMENT AND UP TO $70 MILLION IN ADDITIONAL
PAYMENTS
    * FULCRUM THERAPEUTICS INC - WILL ASSUME SOLE RESPONSIBILITY
FOR
RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION COSTS
AND ACTIVITIES
    * FULCRUM THERAPEUTICS INC - WILL PAY TIERED ROYALTIES ON
FUTURE
COMMERCIAL SALES

Source text for Eikon:  ID:nGNX6GFZjX 
Further company coverage:  FULC.O 

 ((reuters.briefs@thomsonreuters.com;))